Heart failure treatment with stem cells

Using stem cells in the treatment of cardiovascular diseases The method is one of the most promising areas in regenerative medicine. This approach is aimed at restoring damaged areas of the heart, improving blood supply and reducing tissue scarring.

The main aspects of this area are listed below:

Mechanisms of action

• Cell differentiation and replacement: Stem cells (for example, mesenchymal stem cells or cardiac progenitors) can differentiate into cardiomyocytes and vascular cells, which allows replacing lost or damaged heart muscle cells.

• Paracrine action: Stem cells secrete biologically active molecules – growth factors, cytokines and microRNAs, which not only stimulate angiogenesis (formation of new blood vessels), but also reduce inflammation, reduce fibrosis and improve the survival of the remaining cells.

• Modulation of the immune response: Due to their immunomodulatory properties, some types of stem cells can reduce the inflammatory response that aggravates damage to heart tissue. Types of cells used for cardiovascular diseases

• Mesenchymal stem cells (MSCs): Obtained from bone marrow, adipose tissue or umbilical cord blood, MSCs are actively studied in clinical trials for the treatment of myocardial infarction and chronic cardiac ischemia.

• ​​Cardiac stem cells (progenitors): These cells are located directly in the heart and are capable of renewing cardiomyocytes. Their use is aimed at restoring heart tissue after a heart attack.

• Endothelial progenitors: Used to stimulate angiogenesis, which helps improve blood supply to ischemic areas of the heart. The main types of stem cells we plan to use for

Treatment:

MCSs ( mesenchymal stem cells from EMBRYO) - secreting a constellation of active substances, growth factors, cytokines ,inhibit fibrosis and eliminate apoptosis, which is the key to the recovery of the cardiovascular system.

Cardio sphere cells ( from 3d organoids of cardiomyocytes) - show a decrease in the end-diastolic and end-systolic volumes of the ventricles (indicating an improvement in its systolic and diastolic functions). , as well as a reduction in NT-proBNP (an indicator of chronic inflammation and cardiac dysfunction) - in cases with dilated cardiomyopathy.

Microvascular endothelial progenitor cells - improve neogenesis (creation of small vessels for improved nutrition of muscle tissue, its conductivity and contractility).

Exosomes for deep tissue regeneration - they can restart the work of weak and damaged cell, restart their main functions.

Additionally we use cytokines anti-inflammatory complex IL-10, IL-4 + a complex of mitochondria (for energy intercellular exchange). Dosages: MSCs – 240 mln (IV) Cardio cells ( 3d cardiomyocytes) – 90 mln ( IV) MVESCs( p) – 60 mln ( IV) EXO ( DTR) – 36 bln ( IV)

Comments to the diagnosis:

. We plan to use different types of stem cells, but embryotic narrow differentiated cells have the highest success rate in treatment heart fatigue of different etymology. We usually use the combination of some stem cells types with pronounced immunomodulation and proliferative properties, capable of simultaneously reducing inflammation in the affected area and replacing damaged heart cells on their own/

Success rate: Clinical results:

Patients group 65+ years: Patients with myocardial infarction received progenitor EM cells injections. After 6 months, a decrease in scar size and an increase in viable myocardial mass were observed. Left ventricular ejection fraction (LVEF) improved by 16.4% in comparison with other patients without therapy to 1.3% in the control group.( CSP /2018-2024)

Patients group 65+ years: The safety and efficacy of allogeneic cardiomyocytes ( EM) was assessed in patients with ischemic cardiomyopathy. The results showed a decrease in scar size and improved cardiac function by 24-32%, confirming the potential of cells in myocardial regeneration ( CSP/2017-2024)

Patients group 65+ years: Included 166 patients with chronic heart failure and low ejection fraction. Patients received an injection of mesenchymal stem cells (MSCs) of embryonic origin + cardio spheres (EM). After 12 months, a significant reduction in the risk of heart failure decompensation or ventricular arrhythmias was found from 43%-61%).( CPS /2014-2024)

Patients group 65+ years: 24 patients who received allogeneic stem cell of MVSC(p) + cardiomyocytes ( 3d) injections resulted in a reduction in the frequency of attacks. After six months, patients who received stem cell injections had an average of 3.6 chest pain attacks per week, compared to almost twice as many in the control group.

The advantages of our treatment are:

• no of side effects;

• no chemicals involved;

• minimally invasive procedure (intravenous injections);

• no rejection risk;

• no cancer risk;

Our clinic offers the following treatment program: 3 days stem cell treatment (using all kinds of stem cells according to the protocol) The program also includes other bio products and medication preparation for stem cells therapy, stimulation of cell growth and division, control of the immune response.